Neoepitope detection of disease using protein arrays
US-2015355183-A9 · Dec 10, 2015 · US
US9816996B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9816996-B2 |
| Application number | US-201214234783-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2012 |
| Priority date | Jul 26, 2011 |
| Publication date | Nov 14, 2017 |
| Grant date | Nov 14, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
Opening claim text (preview).
The invention claimed is: 1. A method for diagnosis of epithelial ovarian cancer comprising quantitatively detecting a β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and a β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment present in a body fluid derived from a test subject, and determining that the test subject is diagnosed to be likely to have epithelial ovarian cancer when the detection results of the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and the β1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment are greater than a predetermined cut-off value, wherein the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment is detected using at least one antibody or antibody fragment selected from the group consisting of an antibody for detecting an epithelial ovarian cancer marker that recognizes as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1; and a fragment of the antibody for detecting an epithelial ovarian cancer marker that recognizes as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, and wherein the predetermined cut-off value is 95 percentile of the detection results of the β-1,3-N-acetylglucosaminyltransferase 3 polypeptide fragment and the β1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment in body fluid derived from normal individuals or patients other than epithelial ovarian cancer, and wherein the antibody is produced by a hybridoma identified by International Accession No. FERM BP-11494 or FERM BP-11495. 2. The method for diagnosis of epithelial ovarian cancer of claim 1 , wherein the β-1,6-N-acetylglucosaminyltransferase 5B polypeptide fragment is detected using at least one antibody or antibody fragment selected from the group consisting of an anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody recognizing as an epitope a part of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, and a fragment of the anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody, wherein the fragment specifically recognizes β-1,6-N-acetylglucosaminyltransferase 5B. 3. The method for diagnosis of epithelial ovarian cancer of claim 2 , wherein the anti-β-1,6-N-acetylglucosaminyltransferase 5B antibody is produced by a hybridoma identified by International Accession No. FERM BP-11496, FERM BP-11497, FERM BP-11498, or FERM BP-11499. 4. A monoclonal antibody produced by a hybridoma identified by International Accession No. FERM ABP-11494 or FERM ABP-11495. 5. A hybridoma identified by International Accession No. FERM ABP-11494. 6. A hybridoma identified by International Accession No. FERM ABP-11495.
of the ovaries · CPC title
against enzymes · CPC title
Reproductive system, e.g. ovaria, uterus, testes, prostate · CPC title
one of the fusion partners being a B or a T lymphocyte · CPC title
Physics · mapped topic
Related publications grouped by family.
Answers are generated from the same data shown on this page.